Canada-based Eurofins CDMO Alphora boosted its development and production to meet growing demand for both non-potent and high-potency APIs.
The additional suites at the company’s facility located in Mississauga, Canada, covers 627 square feet, and features walk-in fume hoods that support up to 100-liter glass reactors, the company said in a release.
The facility is also supported by an analytical lab and aGMP warehouse and further grows the site’s kilolab that serves as a bridge between small experiments and larger commercial manufacturing.
Financial details of the project weren’t disclosed. The facility currently employs about 250 workers.
“This expansion allows Eurofins CDMO Alphora to better support increasingly complex and highly potent molecules across various stages of development while maintaining a strong focus on quality, safety, and operational excellence,” the company said in a statement.
“The expanded capability also further supports the site’s fully integrated ADC offering, producing linkers and payloads for conjugation with mAbs manufactured on site, significantly reducing timelines and supply chain complexities."
In September 2024, Eurofins kicked off a $64.1 million construction project that saw the CDMO add a 50,000-square-foot facility on its 14-acre Mississauga campus that was designed to produce monoclonal antibodies and protein therapies for clinical and commercial clients.